Research location
Willingboro
New Jersey, United States
Advertisement
Research activity in Willingboro
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 74 trials and 76 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Willingboro
74 linked trials · page 1 of 218 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)NCT04647214 · 2021-03-03 · 1 site observation
COMPLETED
A Twelve Week, Open Label Extension Study in Patients With SchizophreniaNCT01566162 · 2012-04-01 · 1 site observation
COMPLETED
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyNCT01436175 · 2012-02-27 · 1 site observation
TERMINATED
Major Depressive Disorder With Mixed FeaturesNCT01423240 · 2012-01-01 · 1 site observation
WITHDRAWN
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive DisorderNCT01482221 · 2011-12-16 · 1 site observation
COMPLETED
Safety and Efficacy of Vilazodone in Major Depressive DisorderNCT01473381 · 2011-12-01 · 1 site observation
COMPLETED
Study of a Novel Antipsychotic ITI-007 in SchizophreniaNCT01499563 · 2011-12-01 · 1 site observation
COMPLETED
A Study of ALKS 9072 in Subjects With Chronic Stable SchizophreniaNCT01493726 · 2011-12-01 · 1 site observation
COMPLETED
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 DiabetesNCT01474083 · 2011-11-01 · 1 site observation
COMPLETED
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive DisorderNCT01428661 · 2011-09-01 · 1 site observation
COMPLETED
PEARL Schizophrenia MaintenanceNCT01435928 · 2011-09-01 · 1 site observation
COMPLETED
To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic HypertensionNCT01403922 · 2011-08-01 · 1 site observation
TERMINATED
NBRST: Prospective Neo-adjuvant REGISTRY TrialNCT01479101 · 2011-07-01 · 1 site observation
COMPLETED
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual DysfunctionNCT01364649 · 2011-06-01 · 1 site observation
COMPLETED
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive DisorderNCT01377194 · 2011-06-01 · 1 site observation
COMPLETED
Effects of Cariprazine on Cardiac Repolarization in Patients With SchizophreniaNCT01376076 · 2011-06-01 · 1 site observation
COMPLETED
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderNCT01435759 · 2011-05-31 · 1 site observation
COMPLETED
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsNCT01328093 · 2011-04-01 · 1 site observation
TERMINATED
Single Ascending Dose Study of RBP-7000NCT02768649 · 2011-04-01 · 1 site observation
COMPLETED
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)NCT01318434 · 2011-02-01 · 1 site observation
COMPLETED
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of SchizophreniaNCT01234779 · 2011-02-01 · 1 site observation
COMPLETED
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)NCT01235520 · 2011-01-01 · 1 site observation
COMPLETED
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)NCT01192867 · 2010-12-11 · 1 site observation
COMPLETED
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of SchizophreniaNCT01175135 · 2010-10-01 · 2 site observations
COMPLETED
Switching to Iloperidone From Other Antipsychotics in SchizophreniaNCT01207414 · 2010-08-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderNCT01163266 · 2010-07-01 · 1 site observation
COMPLETED
A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving LevodopaNCT01140841 · 2010-06-01 · 1 site observation
COMPLETED
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)NCT01156415 · 2010-06-01 · 1 site observation
TERMINATED
Safety and Efficacy of EVT 101 in Treatment-Resistant DepressionNCT01128452 · 2010-06-01 · 1 site observation
TERMINATED
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01152554 · 2010-06-01 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01153347 · 2010-06-01 · 1 site observation
COMPLETED
Long-term Study of Cariprazine in Patients With SchizophreniaNCT01104792 · 2010-05-31 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)NCT01110902 · 2010-05-01 · 1 site observation
COMPLETED
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable SchizophreniaNCT01163227 · 2010-05-01 · 1 site observation
COMPLETED
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and IncarceratedNCT01157351 · 2010-05-01 · 1 site observation
COMPLETED
Safety and Efficacy of Cariprazine in Patients With SchizophreniaNCT01104766 · 2010-04-23 · 1 site observation
COMPLETED
A Study in Depression and Associated Painful Physical SymptomsNCT01070329 · 2010-03-01 · 1 site observation
COMPLETED
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000NCT02765555 · 2010-03-01 · 1 site observation
COMPLETED
Safety Study of F2695 SR in Major Depressive DisorderNCT01034267 · 2009-12-01 · 1 site observation
COMPLETED
Safety and Cognitive Function Study of EVP-6124 in Patients With SchizophreniaNCT00968851 · 2009-12-01 · 1 site observation
COMPLETED
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of SchizophreniaNCT00977522 · 2009-11-01 · 1 site observation
TERMINATED
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative SymptomsNCT00922272 · 2009-09-14 · 1 site observation
COMPLETED
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderNCT00969709 · 2009-09-01 · 1 site observation
COMPLETED
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderNCT00880048 · 2009-03-11 · 1 site observation
TERMINATED
A Study in the Treatment of Children and Adolescents With Major Depressive DisorderNCT00849901 · 2009-03-01 · 1 site observation
COMPLETED
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic PatientsNCT00845026 · 2009-03-01 · 1 site observation
COMPLETED
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic NeuropathyNCT00857623 · 2009-02-01 · 1 site observation
COMPLETED
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive DisorderNCT00840034 · 2009-02-01 · 1 site observation
COMPLETED
A Study in Adult Patients With Major Depressive DisorderNCT00795821 · 2008-12-01 · 1 site observation
COMPLETED
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic SchizophreniaNCT00789698 · 2008-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.